254 related articles for article (PubMed ID: 25641005)
1. Methods to determine the interactions of micro- and nanoparticles with mucus.
Grießinger J; Dünnhaupt S; Cattoz B; Griffiths P; Oh S; Borrós i Gómez S; Wilcox M; Pearson J; Gumbleton M; Abdulkarim M; Pereira de Sousa I; Bernkop-Schnürch A
Eur J Pharm Biopharm; 2015 Oct; 96():464-76. PubMed ID: 25641005
[TBL] [Abstract][Full Text] [Related]
2. Nano-carrier systems: Strategies to overcome the mucus gel barrier.
Dünnhaupt S; Kammona O; Waldner C; Kiparissides C; Bernkop-Schnürch A
Eur J Pharm Biopharm; 2015 Oct; 96():447-53. PubMed ID: 25712487
[TBL] [Abstract][Full Text] [Related]
3. Undefined role of mucus as a barrier in ocular drug delivery.
Ruponen M; Urtti A
Eur J Pharm Biopharm; 2015 Oct; 96():442-6. PubMed ID: 25770770
[TBL] [Abstract][Full Text] [Related]
4. Mucoadhesion vs mucus permeability of thiolated chitosan polymers and their resulting nanoparticles using a quartz crystal microbalance with dissipation (QCM-D).
Oh S; Borrós S
Colloids Surf B Biointerfaces; 2016 Nov; 147():434-441. PubMed ID: 27568354
[TBL] [Abstract][Full Text] [Related]
5. Nanoparticles decorated with proteolytic enzymes, a promising strategy to overcome the mucus barrier.
Pereira de Sousa I; Cattoz B; Wilcox MD; Griffiths PC; Dalgliesh R; Rogers S; Bernkop-Schnürch A
Eur J Pharm Biopharm; 2015 Nov; 97(Pt A):257-64. PubMed ID: 25661320
[TBL] [Abstract][Full Text] [Related]
6. Development and in vivo evaluation of papain-functionalized nanoparticles.
Müller C; Perera G; König V; Bernkop-Schnürch A
Eur J Pharm Biopharm; 2014 May; 87(1):125-31. PubMed ID: 24373995
[TBL] [Abstract][Full Text] [Related]
7. Mucus permeating thiomer nanoparticles.
Köllner S; Dünnhaupt S; Waldner C; Hauptstein S; Pereira de Sousa I; Bernkop-Schnürch A
Eur J Pharm Biopharm; 2015 Nov; 97(Pt A):265-72. PubMed ID: 25603199
[TBL] [Abstract][Full Text] [Related]
8. Mucus permeating carriers: formulation and characterization of highly densely charged nanoparticles.
Pereira de Sousa I; Steiner C; Schmutzler M; Wilcox MD; Veldhuis GJ; Pearson JP; Huck CW; Salvenmoser W; Bernkop-Schnürch A
Eur J Pharm Biopharm; 2015 Nov; 97(Pt A):273-9. PubMed ID: 25576256
[TBL] [Abstract][Full Text] [Related]
9. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues.
Lai SK; Wang YY; Hanes J
Adv Drug Deliv Rev; 2009 Feb; 61(2):158-71. PubMed ID: 19133304
[TBL] [Abstract][Full Text] [Related]
10. Mucus-penetrating solid lipid nanoparticles for the treatment of cystic fibrosis: Proof of concept, challenges and pitfalls.
Nafee N; Forier K; Braeckmans K; Schneider M
Eur J Pharm Biopharm; 2018 Mar; 124():125-137. PubMed ID: 29291931
[TBL] [Abstract][Full Text] [Related]
11. Lipid-based mucus penetrating nanoparticles and their biophysical interactions with pulmonary mucus layer.
Alp G; Aydogan N
Eur J Pharm Biopharm; 2020 Apr; 149():45-57. PubMed ID: 32014491
[TBL] [Abstract][Full Text] [Related]
12. Overcoming the diffusion barrier of mucus and absorption barrier of epithelium by self-assembled nanoparticles for oral delivery of insulin.
Shan W; Zhu X; Liu M; Li L; Zhong J; Sun W; Zhang Z; Huang Y
ACS Nano; 2015 Mar; 9(3):2345-56. PubMed ID: 25658958
[TBL] [Abstract][Full Text] [Related]
13. Interactions of microbicide nanoparticles with a simulated vaginal fluid.
das Neves J; Rocha CM; Gonçalves MP; Carrier RL; Amiji M; Bahia MF; Sarmento B
Mol Pharm; 2012 Nov; 9(11):3347-56. PubMed ID: 23003680
[TBL] [Abstract][Full Text] [Related]
14. Mimicking microbial strategies for the design of mucus-permeating nanoparticles for oral immunization.
Gamazo C; Martín-Arbella N; Brotons A; Camacho AI; Irache JM
Eur J Pharm Biopharm; 2015 Oct; 96():454-63. PubMed ID: 25615880
[TBL] [Abstract][Full Text] [Related]
15. Functional nanocarrier for drug and gene delivery via local administration in mucosal tissues.
Wang L; Zhou Y; Wu M; Wu M; Li X; Gong X; Chang J; Zhang X
Nanomedicine (Lond); 2018 Jan; 13(1):69-88. PubMed ID: 29173025
[TBL] [Abstract][Full Text] [Related]
16. Development and in vitro evaluation of zeta potential changing self-emulsifying drug delivery systems for enhanced mucus permeation.
Suchaoin W; Pereira de Sousa I; Netsomboon K; Lam HT; Laffleur F; Bernkop-Schnürch A
Int J Pharm; 2016 Aug; 510(1):255-62. PubMed ID: 27329673
[TBL] [Abstract][Full Text] [Related]
17. Development and in vitro evaluation of slippery nanoparticles for enhanced diffusion through native mucus.
Laffleur F; Hintzen F; Shahnaz G; Rahmat D; Leithner K; Bernkop-Schnürch A
Nanomedicine (Lond); 2014 Mar; 9(3):387-96. PubMed ID: 23611618
[TBL] [Abstract][Full Text] [Related]
18. The effect of nanoparticle permeation on the bulk rheological properties of mucus from the small intestine.
Wilcox MD; Van Rooij LK; Chater PI; Pereira de Sousa I; Pearson JP
Eur J Pharm Biopharm; 2015 Oct; 96():484-7. PubMed ID: 25758122
[TBL] [Abstract][Full Text] [Related]
19. Technological strategies to estimate and control diffusive passage times through the mucus barrier in mucosal drug delivery.
Newby JM; Seim I; Lysy M; Ling Y; Huckaby J; Lai SK; Forest MG
Adv Drug Deliv Rev; 2018 Jan; 124():64-81. PubMed ID: 29246855
[TBL] [Abstract][Full Text] [Related]
20. Mucus permeating thiolated self-emulsifying drug delivery systems.
Rohrer J; Partenhauser A; Hauptstein S; Gallati CM; Matuszczak B; Abdulkarim M; Gumbleton M; Bernkop-Schnürch A
Eur J Pharm Biopharm; 2016 Jan; 98():90-7. PubMed ID: 26598209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
